Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 764198 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled, Parallel Group Design)
Latest Information Update: 09 Nov 2021
Price :
$35 *
At a glance
- Drugs BI 764198 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Oct 2020 Results presented in the Boehringer Ingelheim Media Release.
- 15 Aug 2019 Status changed from active, no longer recruiting to completed.
- 02 Aug 2019 Status changed from recruiting to active, no longer recruiting.